nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—embryo—testicular cancer	0.0816	0.232	CbGeAlD
Fluocinonide—SMO—seminal vesicle—testicular cancer	0.0767	0.218	CbGeAlD
Fluocinonide—SMO—female gonad—testicular cancer	0.045	0.128	CbGeAlD
Fluocinonide—Skin striae—Bleomycin—testicular cancer	0.0434	0.0668	CcSEcCtD
Fluocinonide—SMO—testis—testicular cancer	0.0399	0.114	CbGeAlD
Fluocinonide—SMO—lymph node—testicular cancer	0.0289	0.0824	CbGeAlD
Fluocinonide—Telangiectasia—Methotrexate—testicular cancer	0.0237	0.0365	CcSEcCtD
Fluocinonide—Eruption—Dactinomycin—testicular cancer	0.0209	0.0322	CcSEcCtD
Fluocinonide—Folliculitis—Dactinomycin—testicular cancer	0.0205	0.0315	CcSEcCtD
Fluocinonide—NR3C1—embryo—testicular cancer	0.0197	0.0561	CbGeAlD
Fluocinonide—NR3C1—seminal vesicle—testicular cancer	0.0185	0.0527	CbGeAlD
Fluocinonide—Secondary infection—Epirubicin—testicular cancer	0.0178	0.0274	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—testicular cancer	0.0164	0.0253	CcSEcCtD
Fluocinonide—NR3C1—gonad—testicular cancer	0.0134	0.0381	CbGeAlD
Fluocinonide—Skin exfoliation—Bleomycin—testicular cancer	0.0132	0.0203	CcSEcCtD
Fluocinonide—Leukoderma—Methotrexate—testicular cancer	0.0131	0.0202	CcSEcCtD
Fluocinonide—Infection—Carboplatin—testicular cancer	0.0123	0.0189	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—testicular cancer	0.0123	0.0189	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—testicular cancer	0.0114	0.0175	CcSEcCtD
Fluocinonide—Skin exfoliation—Ifosfamide—testicular cancer	0.0113	0.0173	CcSEcCtD
Fluocinonide—NR3C1—female gonad—testicular cancer	0.0109	0.0309	CbGeAlD
Fluocinonide—Pain—Carboplatin—testicular cancer	0.0106	0.0163	CcSEcCtD
Fluocinonide—Skin exfoliation—Cisplatin—testicular cancer	0.0097	0.0149	CcSEcCtD
Fluocinonide—Swelling—Ifosfamide—testicular cancer	0.0097	0.0149	CcSEcCtD
Fluocinonide—NR3C1—testis—testicular cancer	0.00963	0.0274	CbGeAlD
Fluocinonide—Eruption—Methotrexate—testicular cancer	0.00906	0.014	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—testicular cancer	0.00889	0.0137	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—testicular cancer	0.00887	0.0137	CcSEcCtD
Fluocinonide—Eruption—Epirubicin—testicular cancer	0.00848	0.0131	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—testicular cancer	0.0083	0.0128	CcSEcCtD
Fluocinonide—Nasal congestion—Cisplatin—testicular cancer	0.0081	0.0125	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—testicular cancer	0.00785	0.0121	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—testicular cancer	0.00768	0.0118	CcSEcCtD
Fluocinonide—Swelling—Etoposide—testicular cancer	0.00766	0.0118	CcSEcCtD
Fluocinonide—NR3C1—lymph node—testicular cancer	0.00698	0.0199	CbGeAlD
Fluocinonide—Hyperglycaemia—Ifosfamide—testicular cancer	0.00667	0.0103	CcSEcCtD
Fluocinonide—Nasopharyngitis—Cisplatin—testicular cancer	0.00659	0.0102	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—testicular cancer	0.00644	0.00992	CcSEcCtD
Fluocinonide—Infection—Chlorambucil—testicular cancer	0.00631	0.00973	CcSEcCtD
Fluocinonide—Erythema—Bleomycin—testicular cancer	0.00603	0.00929	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—testicular cancer	0.00596	0.00918	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—testicular cancer	0.00562	0.00866	CcSEcCtD
Fluocinonide—Pain—Chlorambucil—testicular cancer	0.00544	0.00838	CcSEcCtD
Fluocinonide—Immune system disorder—Ifosfamide—testicular cancer	0.00535	0.00824	CcSEcCtD
Fluocinonide—Skin exfoliation—Methotrexate—testicular cancer	0.00532	0.0082	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—testicular cancer	0.00516	0.00795	CcSEcCtD
Fluocinonide—Erythema—Ifosfamide—testicular cancer	0.00515	0.00794	CcSEcCtD
Fluocinonide—Pain—Vinblastine—testicular cancer	0.00498	0.00768	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—testicular cancer	0.00498	0.00768	CcSEcCtD
Fluocinonide—Infection—Bleomycin—testicular cancer	0.00489	0.00753	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—testicular cancer	0.00477	0.00735	CcSEcCtD
Fluocinonide—Hypersensitivity—Chlorambucil—testicular cancer	0.00468	0.00722	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—testicular cancer	0.00461	0.0071	CcSEcCtD
Fluocinonide—Immune system disorder—Cisplatin—testicular cancer	0.00461	0.0071	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—testicular cancer	0.00456	0.00702	CcSEcCtD
Fluocinonide—Pruritus—Chlorambucil—testicular cancer	0.0045	0.00693	CcSEcCtD
Fluocinonide—Erythema—Cisplatin—testicular cancer	0.00444	0.00684	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00436	0.00671	CcSEcCtD
Fluocinonide—Hypersensitivity—Vinblastine—testicular cancer	0.00429	0.00661	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—testicular cancer	0.00422	0.00651	CcSEcCtD
Fluocinonide—Pain—Bleomycin—testicular cancer	0.00421	0.00648	CcSEcCtD
Fluocinonide—Infection—Ifosfamide—testicular cancer	0.00418	0.00644	CcSEcCtD
Fluocinonide—Nervous system disorder—Ifosfamide—testicular cancer	0.00412	0.00635	CcSEcCtD
Fluocinonide—Skin disorder—Ifosfamide—testicular cancer	0.00408	0.00629	CcSEcCtD
Fluocinonide—Pain—Dactinomycin—testicular cancer	0.00392	0.00605	CcSEcCtD
Fluocinonide—Dizziness—Vinblastine—testicular cancer	0.00385	0.00594	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00375	0.00579	CcSEcCtD
Fluocinonide—Headache—Vinblastine—testicular cancer	0.00365	0.00562	CcSEcCtD
Fluocinonide—Hypersensitivity—Bleomycin—testicular cancer	0.00362	0.00559	CcSEcCtD
Fluocinonide—Infection—Cisplatin—testicular cancer	0.0036	0.00555	CcSEcCtD
Fluocinonide—Pain—Ifosfamide—testicular cancer	0.0036	0.00554	CcSEcCtD
Fluocinonide—Nervous system disorder—Cisplatin—testicular cancer	0.00355	0.00548	CcSEcCtD
Fluocinonide—Skin disorder—Cisplatin—testicular cancer	0.00352	0.00543	CcSEcCtD
Fluocinonide—Pruritus—Bleomycin—testicular cancer	0.00348	0.00536	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—testicular cancer	0.00347	0.00535	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00344	0.0053	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—testicular cancer	0.00339	0.00522	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—testicular cancer	0.00338	0.00521	CcSEcCtD
Fluocinonide—Infection—Etoposide—testicular cancer	0.0033	0.00508	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—testicular cancer	0.00323	0.00497	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—testicular cancer	0.00321	0.00495	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—testicular cancer	0.00313	0.00483	CcSEcCtD
Fluocinonide—Rash—Bleomycin—testicular cancer	0.0031	0.00478	CcSEcCtD
Fluocinonide—Pain—Cisplatin—testicular cancer	0.0031	0.00478	CcSEcCtD
Fluocinonide—Dermatitis—Bleomycin—testicular cancer	0.0031	0.00478	CcSEcCtD
Fluocinonide—Hypersensitivity—Ifosfamide—testicular cancer	0.0031	0.00477	CcSEcCtD
Fluocinonide—Pruritus—Ifosfamide—testicular cancer	0.00297	0.00458	CcSEcCtD
Fluocinonide—Hyperglycaemia—Epirubicin—testicular cancer	0.00295	0.00455	CcSEcCtD
Fluocinonide—Rash—Dactinomycin—testicular cancer	0.00289	0.00446	CcSEcCtD
Fluocinonide—Pain—Etoposide—testicular cancer	0.00284	0.00438	CcSEcCtD
Fluocinonide—Dizziness—Ifosfamide—testicular cancer	0.00278	0.00428	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—testicular cancer	0.00273	0.00421	CcSEcCtD
Fluocinonide—Hypersensitivity—Cisplatin—testicular cancer	0.00267	0.00412	CcSEcCtD
Fluocinonide—Rash—Ifosfamide—testicular cancer	0.00265	0.00409	CcSEcCtD
Fluocinonide—Dermatitis—Ifosfamide—testicular cancer	0.00265	0.00408	CcSEcCtD
Fluocinonide—Immune system disorder—Methotrexate—testicular cancer	0.00253	0.0039	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—testicular cancer	0.00245	0.00377	CcSEcCtD
Fluocinonide—Erythema—Methotrexate—testicular cancer	0.00244	0.00376	CcSEcCtD
Fluocinonide—Immune system disorder—Epirubicin—testicular cancer	0.00237	0.00365	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—testicular cancer	0.00235	0.00362	CcSEcCtD
Fluocinonide—Rash—Cisplatin—testicular cancer	0.00229	0.00352	CcSEcCtD
Fluocinonide—Dermatitis—Cisplatin—testicular cancer	0.00228	0.00352	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—testicular cancer	0.00228	0.00351	CcSEcCtD
Fluocinonide—Dizziness—Etoposide—testicular cancer	0.0022	0.00338	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—testicular cancer	0.00219	0.00337	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—testicular cancer	0.00211	0.00325	CcSEcCtD
Fluocinonide—Rash—Etoposide—testicular cancer	0.00209	0.00323	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—testicular cancer	0.00209	0.00322	CcSEcCtD
Fluocinonide—Headache—Etoposide—testicular cancer	0.00208	0.00321	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00206	0.00318	CcSEcCtD
Fluocinonide—Infection—Methotrexate—testicular cancer	0.00198	0.00305	CcSEcCtD
Fluocinonide—Nervous system disorder—Methotrexate—testicular cancer	0.00195	0.00301	CcSEcCtD
Fluocinonide—Skin disorder—Methotrexate—testicular cancer	0.00193	0.00298	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00193	0.00297	CcSEcCtD
Fluocinonide—Infection—Epirubicin—testicular cancer	0.00185	0.00285	CcSEcCtD
Fluocinonide—Nervous system disorder—Epirubicin—testicular cancer	0.00183	0.00281	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—testicular cancer	0.00181	0.00279	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00178	0.00275	CcSEcCtD
Fluocinonide—Infection—Doxorubicin—testicular cancer	0.00171	0.00264	CcSEcCtD
Fluocinonide—Pain—Methotrexate—testicular cancer	0.0017	0.00262	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—testicular cancer	0.00169	0.0026	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—testicular cancer	0.00167	0.00258	CcSEcCtD
Fluocinonide—Pain—Epirubicin—testicular cancer	0.00159	0.00245	CcSEcCtD
Fluocinonide—Pain—Doxorubicin—testicular cancer	0.00147	0.00227	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—testicular cancer	0.00147	0.00226	CcSEcCtD
Fluocinonide—Pruritus—Methotrexate—testicular cancer	0.00141	0.00217	CcSEcCtD
Fluocinonide—Hypersensitivity—Epirubicin—testicular cancer	0.00137	0.00211	CcSEcCtD
Fluocinonide—Pruritus—Epirubicin—testicular cancer	0.00132	0.00203	CcSEcCtD
Fluocinonide—Dizziness—Methotrexate—testicular cancer	0.00132	0.00203	CcSEcCtD
Fluocinonide—Hypersensitivity—Doxorubicin—testicular cancer	0.00127	0.00196	CcSEcCtD
Fluocinonide—Rash—Methotrexate—testicular cancer	0.00125	0.00193	CcSEcCtD
Fluocinonide—Dermatitis—Methotrexate—testicular cancer	0.00125	0.00193	CcSEcCtD
Fluocinonide—Headache—Methotrexate—testicular cancer	0.00125	0.00192	CcSEcCtD
Fluocinonide—Dizziness—Epirubicin—testicular cancer	0.00123	0.0019	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—testicular cancer	0.00122	0.00188	CcSEcCtD
Fluocinonide—Rash—Epirubicin—testicular cancer	0.00117	0.00181	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—testicular cancer	0.00117	0.00181	CcSEcCtD
Fluocinonide—Headache—Epirubicin—testicular cancer	0.00117	0.0018	CcSEcCtD
Fluocinonide—Dizziness—Doxorubicin—testicular cancer	0.00114	0.00176	CcSEcCtD
Fluocinonide—Rash—Doxorubicin—testicular cancer	0.00109	0.00167	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—testicular cancer	0.00108	0.00167	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—testicular cancer	0.00108	0.00166	CcSEcCtD
